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We are authors of a large Cochrane review on vitamin C and the common cold [1]. Our review 
includes 63 parallel comparisons of vitamin C and placebo reported in 44 publications [1]. We drew
several conclusions from the large set of trials. However, there may be issues that we did not cover, 
and further analysis of the large set of data is welcome. In this journal, Vorilhon et al. reported a 
meta-analysis in which they examined the effect of vitamin C on common cold in children [2]. 
Nevertheless, we do not consider that their conclusions are valid. Our main concerns are 
summarized below. We include further issues and details in a supplementary file (see below).
1. The authors stated “All trials … comparing the use of vitamin C against placebo were 
selected” [2]. However, one of the included trials administered vitamin C with echinacea and 
propolis [3]. That trial showed significant preventive effects in Vorilhon’s Figure 2, and by far the 
greatest effects on the duration of colds in Figure 3. However, there is no basis to attribute the 
benefits to vitamin C specifically. For example, one meta-analysis concluded that “prophylactic 
treatment with Echinacea products was associated with a reduced risk of experiencing a cold … P < 
0.001” [4]. Propolis may also influence infections. A meta-analysis on vitamin C should restrict to 
trials of vitamin C only [1].
2. Vorilhon wrote that “All trials qualifying as randomized clinical trials (RCTs) ... were 
selected.” However, Coulehan (1974) did not use randomization: “All children were assigned 
alternately, from an alphabetical listing by classroom, to one of two study groups” [5, p 7]. In the 
Cochrane Handbook, which was also cited by Vorilhon [2], alternative allocation is classified as an 
“inadequate method of sequence generation” [6]. A meta-analysis restricted to randomized trials 
should exclude Coulehan (1974), but, if it is included, the review should not state that it restricts to 
randomized trials.
3. Ludvigsson reported two separate trials [7], but Vorilhon [2] did not include the smaller 
“pilot” trial, although that was larger (N = 158) than three included trials (N = 39 to 60). In the 
supplementary file by Vorilhon, the Coulehan (1976) trial [8] is both excluded and included; and in 
Figure 2 it is included whereas in Figure 3 it is excluded though Coulehan published the outcomes 
shown in both figures. No justification is given for these inconsistencies [2].
4. Vorilhon [2] gave SD values for three comparisons from two reports [5,9] without describing
their source. The original reports did not publish the SD values. Although it is appropriate to impute
SD values [6], the methods should be described if imputation is used. Furthermore, for the Ritzel 
trial Vorilhon gave SD values that led to P = 0.238 in Figure 3. However, Ritzel stated that the study
groups significantly deviated one from another with “P < 0.05; t-distribution” [9]. Thus, Vorilhon’s 
SD values are incompatible with the Ritzel report.
5. In the Results section, Vorilhon wrote: “the duration of URTI was decreased by 1.6 days 
(26%) in the vitamin C group” [2]. The calculation of this result was not reported. Figure 3 is the 
forest plot for the analysis of cold duration on the SMD (standardized mean difference) scale, which
means the calculation of the effect in the SD units. However, the effect in SD units does not 
transform to an effect in days or %-units.
6. The assessment of methodological quality was inconsistent. In Table 2, Vorilhon put a 
question mark for “incomplete outcome data” for the Ludvigsson trial, which indicates that there is 
potential bias. Ludvigsson reported that 96% (615/642) of participants continued to the end of the 
“main” trial [7]. In contrast, Vorilhon did not question the Coulehan (1974) trial, which reported 
“Six hundred and forty-one of the 666 children (96 per cent) completed the entire 14-week study 
period” [5, p. 7]. These two trials had identical dropout rates, but they were assessed differently. 
7. Vorilhon et al. allege our 2013 review [1] had limitations. In the introduction, they write: 
“A meta-analysis from 2013 assessed the efficacy of vitamin C for prevention and treatment of the 
common cold, but the review had limitations: ... it included one trial that contained manifestly 
incorrect data” [2, p. 304]. However, Vorilhon did not explain what they meant by that statement, 
which particular trial “contained manifestly incorrect data”, or how the data was incorrect. This is a 
strong accusation about the validity of our review which we consider is unjustified.
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commenting Vorilhon (2019) meta-analysis: 
 
 
Vorilhon P, Arpajou B, Vaillant Roussel H, Merlin É, Pereira B, Cabaillot A.  
Efficacy of vitamin C for the prevention and treatment of upper respiratory tract 
infection. A meta-analysis in children.  
Eur J Clin Pharmacol 2019;75(3):303-311 
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Here we give additional information for the issues 1 to 6 listed in our letter-to-the-editor,  
and we also describe additional concerns from 7 to 13.  
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1. Inclusion of a trial that did not study vitamin C alone 
 
Vorilhon wrote “All trials … comparing the use of vitamin C against placebo were selected.” 
However, the included Cohen (2004) trial also administered echinacea and propolis to the 
“vitamin C” group. Thus, that is not a “vitamin C” trial but it is a “vitamin C + echinacea + 
propolis” trial and should not be included in an analysis of “vitamin C” alone.  
https://doi.org/10.1001/archpedi.158.3.217  
https://www.ncbi.nlm.nih.gov/pubmed/14993078  
 
Vorilhon wrote “Cohen’s RCT [23], … While echinacea has not been shown to be effective in 
reducing the incidence and duration of URTIs [26]”. 
We do not consider that this statement justifies the inclusion of the Cohen trial, given that 
echinacea was administered with vitamin C. “Absence of evidence is not evidence of absence”  
is a basic principle in medical statistics, eg 
https://www.ncbi.nlm.nih.gov/pubmed/8937675  
https://www.ncbi.nlm.nih.gov/pubmed/14988165  
https://www.ncbi.nlm.nih.gov/pubmed/25085689  
Thus, “has not been shown to be effective” does not mean that echinacea “has been shown to be 
equivalent to placebo”. 
We believe, Vorilhon misrepresents the findings of the Cochrane review [ref 26 in their paper]. 
Echinacea is not a well-defined product, instead different trials have tested different kinds of 
echinacea extracts. In any case, the Cochrane review on echinacea and the common cold stated: 
“in our exploratory meta-analysis pooling all trials (1167 patients totally), regardless of the product 
used, prophylactic treatment with Echinacea products was associated with a reduced risk of 
experiencing a cold (RR 0.83, 95% CI 0.75 to 0.92; P < 0.001).” 
see page 13, left-hand column line 4 forward: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068831  
Such very strong evidence for “prophylactic treatment with Echinacea products” refutes 
Vorilhon’s assumption that echinacea is ineffective and can be administered with vitamin C without 
echinacea influencing the perceived vitamin C effect. 
 
Furthermore, no justification is given for their assumption that propolis is an ineffective 
component of the Cohen trial. There are RCTs that have reported benefits of propolis: 
“The administration of a propolis and zinc suspension to children with a history of rAOM 
[recurrent acute otitis media] can significantly reduce the risk of new AOM episodes.” 
https://www.ncbi.nlm.nih.gov/pubmed/20646352  
“Propolis plus bicarbonate was safe, well tolerated and promisingly effective in the prevention 
of OM [oral mucositis] in patients with breast cancer.” 
https://www.ncbi.nlm.nih.gov/pubmed/28840622  
“Propolis is produced by bees and is reported to have several pharmaceutical properties. Its 
antibacterial activity against strains causing upper respiratory tract infections is particularly 
important: propolis might be used as a therapeutic agent to prevent the bacterial infections that 
sometimes overlap viral infections.” 
https://www.ncbi.nlm.nih.gov/pubmed/16736885  
“Propolis may have a role in the treatment of (aphthous) stomatitis, mouth ulcer and prevention 
of acute otitis media.” 
https://www.ncbi.nlm.nih.gov/pubmed/26453201   
“Varicella zoster virus ... The propolis extract exhibited high levels of antiviral activity against 
VZV in viral suspension tests, infectivity was significantly reduced by 93.9 % and a direct 
concentration-dependent antiviral activity could be demonstrated.” 
https://www.ncbi.nlm.nih.gov/pubmed/30522559  
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Thus, there is no justification to assume that propolis is equivalent to placebo in a common cold 
trial. 
When the selection criterion for trials is “RCTs comparing the use of vitamin C against 
placebo”, it is not appropriate to include a “vitamin C + echinacea + propolis” trial. It is not a 
“vitamin C” trial. 
 
 
Furthermore, the Cohen RCT [23] is highly influential in Vorilhon’s review. 
 
The Cohen trial shows significant preventive effects in Vorilhon's Figure 2 and it is by far the 
most positive study in Figure 3. In addition, the Cohen trial is the only study that had children under 
6 years (see Table 1 in Vorilhon). 
In the Abstract, Vorilhon wrote “Children under 6 years of age benefit from more effective 
vitamin C supplementation associated with echinacea” and in the Conclusion section they write 
“Vitamin C supplementation appears to be more effective for children under 6 years of age”. 
Those sentences are based fully on the Cohen trial, so that its exclusion would lead to a 
substantial revision of the conclusions even at the Abstract level. 
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2. Inclusion of a trial that was not a randomized trial 
 
In their statement of Study selection, Vorilhon wrote “All trials qualifying as randomized 
clinical trials (RCTs) ... were selected.” 
The Coulehan (1974) trial was not randomized, but it was an alternative allocation trial (p 7): 
 
 
 
 
 
Coulehan JL, Reisinger KS, Rogers KD, Bradley DW. Vitamin C prophylaxis in a boarding 
school. N Engl J Med. 1974;290(1):6-10.  
https://doi.org/10.1056/NEJM197401032900102  
https://www.ncbi.nlm.nih.gov/pubmed/4586102  
 
 
In the Cochrane Handbook, alternative allocation is classified under the subtitle “Inadequate 
methods of sequence generation”. It is described with the comment “sometimes referred to as quasi-
random”: 
https://handbook-5-1.cochrane.org/chapter_8/8_9_2_2_inadequate_methods_of_sequence_generation.htm  
Vorilhon should have either excluded the Coulehan (1974) trial since it was not a randomized 
trial, or should have stated that quasi-randomized trials were included. 
Vorilhon’s ref 13 is the same Cochrane Handbook to which we give the link above. In the 
Methods section (p. 304) Vorilhon wrote “This study followed …  Cochrane Handbook guidance 
standards [13]” but that did not occur in the selection of trials process. 
 
 
 
 
5 
3a) Exclusion of the Ludvigsson “pilot” study without justification 
 
Ludvigsson (1977). reported two separate trials, the “pilot” trial and the “main” trial, but 
Vorilhon included only the “main” trial and not the “pilot” trial. 
Ludvigsson J, Hansson LO, Tibbling G. Vitamin C as a preventive medicine against common 
colds in children. Scand J Infect Dis. 1977;9(2):91-8.  
https://www.ncbi.nlm.nih.gov/pubmed/897573   
https://www.mv.helsinki.fi/home/hemila/CC/Ludvigsson_1977_bm.pdf  
https://www.mv.helsinki.fi/home/hemila/CC/Ludvigsson_1977_ch.pdf   
 
In Table 1, Vorilhon writes of the Ludvigsson (1977) trial: “1 g/day in the intervention group 
and 30 mg/day of vitamin C in the placebo group for the pilot study during 7 weeks” as one 
paragraph and “1 g/day in the intervention group and 10 mg/day of vitamin C in the placebo group 
for the main study during 12 weeks” in another paragraph. 
In the Discussion, Vorilhon write (p. 310) that “In the RCT by Ludvigsson et al. [20], the 
placebo contained a small dose of vitamin C (10 mg in the main study and 30 mg in the pilot 
study).” Thus, Vorilhon recognized that there were two separate RCTs reported in the Ludvigsson 
paper (ie the “main” and “pilot” trials). 
 
Ludvigsson reported (p. 95):  
The “pilot study” had 78 + 80 = 158 participants 
The “main study” had 311 + 304 = 615 participants 
Only the “main study” is included in Vorilhon Figures 2 and 3. 
 
In systematic reviews, all identified relevant RCTs should be either rejected with an explicit 
reason, or they should be included in the analysis. 
The paper and supplementary file of Vorilhon do not give any justification for excluding the 
“pilot study” of Ludvigsson from the forest plots presented in Figure 2 and Figure 3. 
This is not a trivial issue. Although the 158 participants was a “pilot study” for Ludvigsson 
(1977), the 158 participants is considerably more than the number of participants: 
N = 62 in Bancalari 
N = 39 in Constantini 
N = 88 (=44 twin pairs) in Miller; (see Table 1 of the Vorilhon paper). 
 
 
3b) Simultaneous inclusion and exclusion of the Coulehan (1976) trial 
 
The Coulehan (1976) trial  
http://dx.doi.org/10.1056/NEJM197610282951802  
https://www.ncbi.nlm.nih.gov/pubmed/787788  
is both excluded and included in the supplementary file for the Vorilhon paper. 
It is listed in Supplement Table 5: “Qualitative analysis of excluded trials” 
but it is also listed in Supplement Table 6: “Risk of bias in the [included] studies” 
 
In the Results section of the Vorilhon paper, the Coulehan (1976) trial is included in Figure 2 
which describes the incidence of colds, but it is not included in Figure 3 which describes the 
duration of colds, although Coulehan (1976) reported the duration of colds even in their Abstract: 
“There was no difference in ... mean illness duration (5.5 versus 5.8 days) between the [vitamin 
C and placebo] groups” https://www.ncbi.nlm.nih.gov/pubmed/787788  
Vorilhon does not give an explanation as to why this trial is both excluded and included in the 
supplement, and why it is included in Figure 2 but not in Figure 3. 
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4. SD values without sources 
 
4a) SD values for the Coulehan (1974) trials with 1 and 2 g/day of vitamin C 
 
In Table 3, Vorilhon stated that the SD values for the Coulehan (1974) trial were 4.8 days in the 
treated (vitamin C) groups and 6.4 days in the control (placebo) groups for both the 1 g/day and the 
2 g/day dosage. 
 
Coulehan JL, Reisinger KS, Rogers KD, Bradley DW. Vitamin C prophylaxis in a boarding 
school. N Engl J Med. 1974;290(1):6-10. 
https://doi.org/10.1056/NEJM197401032900102  
http://www.ncbi.nlm.nih.gov/pubmed/4586102  
 
Coulehan (1974) reported the duration of “respiratory illness” as follows in Table 2 (below): 
4.95 days and 5.65 days for the Lower grades children (1 g group in Vorilhon Fig. 3). 
and 
4.44 days and 6.29 days for the Upper grades children (2 g group in Vorilhon Fig. 3). 
However, Coulehan (1974) did not report the SD for the above-mentioned mean values: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a meta-analysis, it is appropriate to “impute” variables such as SD and SE. For example, if 
the mean difference and the P-value are reported, the SE value can be calculated as an “imputed” 
value (a P-value can be back-transformed to a z or t-value), even when the SE was not reported. 
This is described in the Cochrane Handbook section 16.1.3.1 on “Imputing standard deviations”: 
https://handbook-5-1.cochrane.org/chapter_16/16_1_3_1imputing_standard_deviations.htm  
However, if imputation of SD values is used, the researchers should describe the method of 
imputation, but none was given by Vorilhon. There is no description in their paper about the source 
of the SD values 4.8 and 6.4 days for the Coulehan (1974) trial and it is not clear how they were 
calculated. 
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4b) SD values for the Ritzel trial 
 
For the Ritzel (1961) trial, Vorilhon reported the SD values as 4.8 days in the treated (vitamin C) 
groups and 6.4 days in the control (placebo) groups. These figures gave P = 0.238 in Figure 3 of the 
Vorilhon paper.  
 
Ritzel G. Critical evaluation of vitamin C as a prophylactic and therapeutic agent in colds. 
[in German]. Helv Med Acta. 1961;28:63-8.  
http://www.mv.helsinki.fi/home/hemila/CC/Ritzel_1961_ch.pdf  
http://www.mv.helsinki.fi/home/hemila/CC/Ritzel_1961_bm.pdf  
http://www.ncbi.nlm.nih.gov/pubmed/13741912  
https://www.mv.helsinki.fi/home/hemila/T3.pdf  Translation 
 
Ritzel published the results as follows: 
 
 
 
 
 
 
 
 
 
Translation: 
“In this connection, too, evaluation of the results from the therapeutic perspective appeared to 
us to be of interest. In this regard we compared the average length of sickness for both groups. In 
the case of the group treated with vitamin C it was 1.8 days versus 2.6 days for the group that 
received placebos. These averages, too, deviate statistically significantly one from the other (P < 
0.05; t-distribution).” see: https://www.mv.helsinki.fi/home/hemila/T3.pdf  
 
Ritzel does not report SD values in that section of text, nor in any other part of the 1961 report. 
Here it is obvious that the SD values published by Vorilhon cannot originate from imputation, since 
Vorilhon’s resulting P-value (P = 0.238) is inconsistent with the P-value published by Ritzel (P < 
0.05). If imputation is used, the imputed SD values should be consistent with the published P-value. 
 
It is also quite surprising that the SD values for the Ritzel trial are identical to the SD values for 
both the 1 g and the 2 g trials of the Coulehan (1974) report, i.e. SD 4.8 days in the treated (vitamin 
C) groups and SD 6.4 days in the control (placebo) groups for each of the three trials. If imputation 
was used, it is highly unlikely that the calculated SD values would be identical in three trials.  
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5. “Vitamin C administration was found to decrease the duration of URTI by 1.6 days”  
(Abstract, Vorilhon) 
“the duration of URTI was decreased by 1.6 days (26%) in the vitamin C group” 
(Results, Vorilhon) 
“Vitamin C administration decreased the duration of URTI by 1.6 days” and  
“a decrease of 1.6 days of URTI may represent a potential reduction in the inappropriate 
prescribing of ineffective or even potentially dangerous antibiotics”  
(Discussion, Vorilhon) 
 
There is no reported calculation or forest plot in the paper, which describes the origin of the 
reported 1.6 day and 26% effect. 
Figure 3 is the forest plot for the analysis on the SMD (standardized mean difference) scale, 
which means the calculation of the vitamin C effect in SD units. However, the effect in SD units 
does not transform to the effects in days or %-units. If a researcher is interested in the effect of 
vitamin C on the duration in days, then the meta-analysis must be carried out on the days scale, and 
if the researcher is interested in the %-effects, then the meta-analysis needs to be done on the 
relative scale. 
For example, let us assume that there are two trials that observe identical common cold duration 
in two study groups, 6 days for the vitamin C groups and 7 days for the placebo groups. This means 
that both trials show that vitamin C reduces the length of colds by one day (or 14%). However, if 
one of the two studies has more homogeneous common cold durations, which means a smaller SD, 
whereas the other study has more heterogeneous common cold durations, which means a larger SD, 
then the two trials show substantially different treatment effects on the SMD-scale, even though the 
effect on the “days” scale and the %-scale was identical. 
The converse is also true. Thus, studies with an identical effect on the SMD-scale can have 
substantially different effects on the “days” and %-scales. Therefore, an effect on the SMD-scale 
cannot be transformed to a days effect or a percentage effect. 
Vorilhon does not describe the statistical origin for the reported 1.6 days and the 26% effects. 
The 1.6 day value is published in the Abstract, so that the validity of this estimate is important even 
for the validity of the Abstract. 
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6. Assessment of methodological quality is inconsistent 
 
In Table 2 (risk of bias summary), Vorilhon put a question mark for “Incomplete outcome data” 
for the Ludvigsson (1977) trial, but not for the Coulehan (1974) trial. A question mark indicates that 
that there is potential bias in the quality item. 
Ludvigsson wrote that in their “main study” (p. 91):  
 
 
 
 
Thus, 96% of participants who took part (615/642), continued to the end of the trial. 
In the supplementary file, Vorilhon wrote about the Ludvigsson trial: 
“Losses to follow-up were high and it is not known whether this affects one group more than the 
other.” 
Vorilhon does not give a quantitative justification for this statement. 
There does not seem to be any basis to claim that a 4% drop-out rate in a 3-month trial is so high 
that it is likely to cause substantial bias in the findings. 
Coulehan (1974) wrote (p. 7):  
 
 
 
 
 
 
 
Thus, the Ludvigsson (1977) “main” trial and the Coulehan (1974) trial both had the same 4% 
drop-out rate (which is very low), but Vorilhon considered that the 4% dropout was a problem in the 
Ludvigsson trial, but not in the Coulehan (1974) trial, without any justification for the 
inconsistency. 
 
In Table 2 (Risk of bias table), Vorilhon puts a question mark for “blinding of participants and 
personnel” for Bancalari, Constantini, Cohen and Miller trials. 
However, in the Results section “Trials included” (p. 305), Vorilhon writes 
“Eight double-blind RCTs met the inclusion criteria… The trials were randomized, placebo-
controlled, and double-blind.” 
Double blind means that both the participants and the researchers were blinded.  
Given that Vorilhon described the trials as “placebo-controlled, and double-blind”, there should 
be an explanation as to why they put question marks against this quality item. No justification is 
provided in the supplementary file. 
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7) Vorilhon alleges our 2013 Cochrane review had limitations 
 
 
Our Cochrane review: 
https://doi.org/10.1002/14651858.CD000980.pub4  
https://helda.helsinki.fi/handle/10138/225864  
http://www.mv.helsinki.fi/home/hemila/CC/2013_Coch_Colds_CD000980.pdf  
 
 
 
7a) In the Introduction (p 304) Vorilhon refers to our Cochrane review [ref 11 in Vorilhon]: 
 
“A meta-analysis from 2013 assessed the efficacy of vitamin C for prevention and treatment of 
the common cold [11], but the review had limitations: ... (2) it included one trial that contained 
manifestly incorrect data.” 
 
However, Vorilhon did not describe what they mean by that statement, either in their paper or in 
the supplement. They did not report which particular trial “contained manifestly incorrect data”, 
and how the data was incorrect. 
This is a strong accusation about the validity of our Cochrane review indicating that we have 
been sloppy. Given the lack of any specific description about the identity of the trial, and the kind of 
“manifestly incorrect data” in that particular trial, we consider that this is an unjustified accusation. 
If Vorilhon has knowledge that we are unaware of about one of our included trials, we would be 
very keen to learn of it. 
 
 
7b) In the Introduction (p 304) Vorilhon refers to our Cochrane review [ref 11 in Vorilhon]: 
 
“A meta-analysis from 2013 assessed the efficacy of vitamin C for prevention and treatment of 
the common cold [11], but the review had limitations: (1) it did not specifically evaluate the effect of 
vitamin C on the incidence of URTI in children and adolescents.” 
 
Vorilhon uses this statement as a justification for their analysis of vitamin C on common cold 
incidence in children. However, in our Cochrane review we showed that there was statistically 
significant heterogeneity over 29 trials on adults and children (P = 0.02 in the heterogeneity test). 
We showed that the heterogeneity was explained by the experimental conditions. In trials carried 
out in the general community, there was no evidence that vitamin C influenced the incidence of 
colds, with RR = 0.97 (95% CI 0.94 to 1.00). In contrast, in five trials carried out with participants 
under heavy short-term physical stress, vitamin C reduced the incidence of colds by RR = 0.48 
(95% CI 0.35 to 0.64; z = 4.00, P < 0.00001). The Ritzel (1961) trial with schoolchildren in a short 
skiing camp in Swiss Alps falls to the latter group of five trials. Thus, the benefit reported by Ritzel 
seemed to be explained by the harsh conditions of the skiing camp, and not by the young age of the 
participants. The set of 24 trials with participants in the “general community” includes several trials 
with children, with all of them being consistent with the lack of effect. 
Although further research on vitamin C and common cold incidence is welcome, new research 
should take into account the findings of previous meta-analyses, such as the effect of heavy short-
term physical stress in the analysis on vitamin C and common cold incidence. 
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7c) In the Discussion (p 309) Vorilhon refers to our Cochrane review [ref 11 in Vorilhon]: 
 
“It is noteworthy that Hemilä’s review and analysis did not distinguish between children and 
adults with regard to the primary endpoint, but only with regard to the secondary endpoints. If the 
data on the primary endpoint are stratified to separate children and adults, the preventive effect of 
vitamin C is no longer found in children (p = 0.42).” 
 
It is not clear to us, what Vorilhon means with the statement “If the data on the primary endpoint 
are stratified to separate children and adults, the preventive effect of vitamin C is no longer found in 
children (p = 0.42).” 
When all 29 preventive vitamin C trials were pooled in the Cochrane review, we calculated RR 
= 0.95 (95% CI 0.92 to 0.98). We commented “Although the overall difference between vitamin C 
and placebo participants is statistically highly significant (P = 0.001), indicating a biological effect 
of vitamin C, the narrow CI precludes any clinically relevant effect over wide population groups” 
(p. 12). 
Thus, we stated that such a narrow confidence interval close to the null effect did not indicate 
any practical benefits of vitamin C. Therefore, we cannot understand what Vorilhon meant by “the 
preventive effect of vitamin C is no longer found in children” when we had not proposed that there 
might be a meaningful preventive effect of vitamin C for children and adults over all 29 trials. 
As described above in 7b, in our Cochrane review we showed that physical stress explained the 
significant heterogeneity over the 29 trials. Given this, the prevention trials should first be stratified 
by physical stress, and secondarily by children and adults. However, in the general community 
trials, we found that there was no preventive effect from vitamin C for trials in children or adults. In 
the five physical stress trials, the trials in both children (i.e. the Ritzel trial) and adults are consistent 
with vitamin C halving common cold incidence. Therefore, stratifying by age (children/adults) does 
not give any additional information after the stratification by the heavy short-term physical stress. 
Thus, Vorilhon misunderstands our findings on the role of physical stress and leads the reader to 
believe that the children vs. adult stratification may have influenced our conclusions. This is not 
correct. 
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8) Vorilhon used OR (odds ratio) for estimating the preventive effect of vitamin C 
 
In Figure 2, Vorilhon used the OR scale to calculate the effect of vitamin C on common cold 
incidence. OR is a useful approximation of RR in case-control studies. However, this approximation 
is only valid for rare events. Common cold events are not rare. Furthermore, for RCT results there is 
no reason to calculate the OR estimates, since the RR can be directly calculated from the RCT 
results, which is not the case for case-control results. 
 
For example, Altman wrote that “the odds ratio [OR] should not be interpreted as an 
approximate relative risk [RR] unless the events are rare in both groups (say, less than 20–30%)” 
https://www.bmj.com/content/317/7168/1318.1  
 
In the Bancalari trial, the incidence of colds was 21/32 (66%) in the vitamin C group and 21/30 
(70%) in the placebo group. 
In the Ludvigsson “main” trial, the incidence of colds was 230/304 (75%) in the vitamin C 
group and 240/311 (77%) in the placebo group. 
These incidence levels are much higher than the upper limit suggested by Altman. 
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9) The data used by Vorilhon for calculating Ritzel trial OR appears inconsistent with the 
published Ritzel results 
 
In Figure 2, Vorilhon calculated that the incidence of colds was decreased in the Ritzel trial by 
OR = 0.36 (95% CI 0.23 to 0.54). 
 
In our Cochrane (2013) review, we state that the Ritzel trial had 17 colds in 139 vitamin C 
participants, and 31 colds in 140 placebo participants. The 17 and 31 colds were not reported by 
Ritzel, but we derived them using the following calculation. 
In Table 1 (below), Ritzel reported that there were 31 sickness days in the vitamin C group.  
In the text section Ritzel reported that the duration of colds was 1.8 days in the vitamin C group (see 
p. 7 of this text)  
 
 
 
 
 
 
 
 
 
 
 
The study lasted over “5 to 7 day long ski camps” (1st paragraph of Results in the Ritzel report) 
and thus it is reasonable to assume that there was not more than 1 cold episode per person during 
such a short trial in a skiing camp. 
This gives, 31/1.8 = 17.2 colds in the vitamin C group. 
Similarly, 80/2.6 = 30.8 colds in the placebo group. 
These round to 17 and 31, which we use as estimates for the number of colds in our Cochrane 
review. 
Calculation of the OR for the above data gives 
OR = [17/(139-17)]/[31/(140-31)] = [17/122]/[31/109] = 0.139/0.284 = 0.49. 
 
In Figure 2, Vorilhon reports that the effect of vitamin C in the Ritzel trial was OR = 0.36. 
We suspect that the OR = 0.36 is erroneous. It is inconsistent with the incidences that we 
describe above. Vorilhon does not describe how they extracted the incidence data for the Ritzel trial, 
which they used in the calculation of their OR = 0.36. 
 
Furthermore, the confidence interval that Vorilhon reported, ie, (95% CI 0.23 to 0.54) 
corresponds to P(2-t) = 0.00003. 
This is based on the following calculation: 
ln(0.54) - ln(0.23)  = 2*1.96*SE, which gives SE = 0.218 
The OR-effect on the logarithmic scale is ln(0.36) = 1.02 = Effect 
Thus, z = Effect/SE = 1.02/0.218 = 4.69, which corresponds to P(2-t) = 0.000003. 
 
However, the Fisher exact test for the 2×2 table [17/122]/[31/109] gives P = 0.0385. 
This can be calculated with various web-based calculators, eg. 
https://www.socscistatistics.com/tests/fisher/default2.aspx  
https://www.graphpad.com/quickcalcs/contingency2  
http://vassarstats.net/tab2x2.html  
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The 95% CI for the OR can also be calculated for [17/122]/[31/109],  
http://vassarstats.net/odds2x2.html  
giving 
OR 0.49 (95% CI 0.26 to 0.93), which is quite close to the RR that we calculated in our 
Cochrane review: RR 0.55 (95% CI 0.32 to 0.95). 
 
Thus, there seem to be significant errors in the calculation of the OR of the Ritzel trial by 
Vorilhon. 
 
Overall, Vorilhon do not describe in their paper or in their supplementary file the extracted 
incidence values for the Figure 2 trials. For the transparency of a meta-analysis it is essential that 
the extracted data are described so that a critically minded reader can check the data and the 
statistical processes. 
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10) Incorrect statement about the Ritzel trial 
 
Vorilhon wrote “It was not possible to obtain individual-level data from Ritzel et al.; in their 
RCT, the results were reported in sickness days and it was not possible to extract or analyze the 
data” (p. 309). 
 
This sentence misleads the reader. There are no individual-participant data (IPD) for any of the 
old trials: Coulehan (1974), Coulehan (1976), Ludvigsson (1977), Miller (1977), Bancalari (1984). 
There are only mean values for the vitamin C and placebo groups, with SD for some trials but not 
for all. In addition, Vorilhon does not describe that they have used IPD in any analyses of the other 
trials. Thus, the existence, or lack of existence, of IPD for the Ritzel trial has no consequences. 
 
Vorilhon’s statement makes the reader believe that the Ritzel trial is particularly poor. The Ritzel 
trial was published in 1961 and the standards of reporting were very different compared with 
current standards. However, the Ritzel trial should not be singled out for the lack of IPD when that 
is not available for other trials, and when Vorilhon does not report any analyses of IPD. 
 
Furthermore, Vorilhon does include the Ritzel trial in both Figure 2 and Figure 3 and thus it was 
“possible to extract and analyze the data” although the above sentence claims that it was not 
possible to extract or analyze the Ritzel data. 
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11) No consideration about the complexity of the common cold 
 
Vorilhon writes in the Abstract: 
“Vitamin C administration was found to decrease the duration of URTI by 1.6 days” 
and in the Discussion: 
“For an average duration of 6 days, a decrease of 1.6 days of URTI may represent a potential 
reduction in the inappropriate prescribing of ineffective or even potentially dangerous antibiotics” 
As described above, the 1.6 days estimate is not based on any reported statistical analysis. 
However, even if the 1.6 days was a valid estimate, the interpretation of such an estimate is not 
straightforward and should be considered thoroughly in the Discussion. 
 
The Ludvigsson (1977) “main” trial is particularly informative on this issue. 
 
In the “main study” (p. 95) with 615 participants, Ludvigsson found no effect on: 
“cold symptoms from the nose” or 
“upper respiratory tract infection” 
 
However, Ludvigsson found a significant (t = 2.42, P = 0.016) effect on: 
“absence from school because of URTI” 
The effect of vitamin C was a 0.45 day (14%) reduction in days absent from school (2.77 days 
in the vitamin C group vs. 3.22 days in the placebo group) 
 
Thus, the effect of vitamin C may be different depending on the particular common cold 
outcome. A large trial by Terrence Anderson (1972) with adults also found a significant (t = 2.45,  
P = 0.014) effect on time “confined indoors”, but no effect on the “duration of symptoms” (Table 
II). Anderson (1972) found a 0.28 day reduction in “days confined indoors” (1.04 days in the 
vitamin C group vs. 1.32 days in the placebo group). 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940935  
 
If the symptoms are mild, such that the patient has a runny nose but can go to school or work 
without functional limitations, reduction in the duration of runny nose by, say, 1.6 days might not 
have practical consequences. 
On the other hand, if “days off school” or “days confined indoors” is shortened by 1.6 days per 
episode, that might be a substantial effect. However, there is no basis to assume that the 1.6 days is 
a reasonable estimate for the effect of vitamin C on “days off school”. The most informative 
estimate for the effect on “days off school” is from the Ludvigsson (1977) "main trial" which is a 
reduction of 0.45 days which is much smaller than 1.6 days. 
Furthermore, the cost-benefit should be considered. Does a child need to take vitamin C for half 
a year to shorten “days off school” by half a day? What is the cost of taking vitamin C for half a 
year? Vorilhon ignores the complexity of “the common cold”. 
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12) Many numbers are inconsistent in different parts of the paper 
 
Figure 1 (the flow chart) describes that 7 trials were included in the quantitative analysis. 
 
Table 1 lists 8 trials in the “Authors” and “No [the number of] participants” columns, but 9 trials 
in the “doses and duration” column. This discrepancy is explained by mentioning the Ludvigsson 
“pilot” study in “doses” but not in “No participants”. 
Figure 2 has 7 trials with Coulehan (1974) as a single trial and the Miller trial excluded and 
Figure 3 has 8 trials with Coulehan (1974) as two trials and the Coulehan (1976) excluded. 
The abstract states “Eight RCTs, including 3135 children” 
The discussion states: “Statistical analysis of seven RCTs, including 3135 children” 
Thus, the number of included trials varies between 7 and 9. The number of included trials 
should be consistent throughout the article. 
 
Furthermore, we calculated the number of participants in Table 1 from the “No participants”: 
62+328+39+641+868+615+44+279 = 2876. 
Vorilhon states there are 3135 participants in the Abstract and Discussion, so there are 259 
participants missing between the Abstract and Table 1. 
 
The Results section states: “The dose of vitamin C varied from 0.5 to 2 g/day” 
The Discussion states: “The vitamin C dosage delivered differed between RCTs (2 g/day in 
Bancalari et al. [19] and 100 mg in Cohen et al. [18]).” 
Thus, the lowest dose in the Results is 0.5 g/day but in the Discussion it is 0.1 g/day. This should 
also be consistent. 
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13) Erroneous statements in the Introduction, misleading the readers 
 
In the third paragraph Vorilhon writes: 
 
“Vitamin C was used heavily in the 1970s in the wake of Pauling’s clinical trials concluding that 
vitamin C prevents URTI and improves URTI symptoms [5–7].” 
 
In actual fact, Pauling did not carry out any clinical trials on vitamin C and URTI. He published 
two meta-analyses of placebo-controlled trials carried out by other researchers, both were published 
in 1971: 
https://dx.doi.org/10.1073%2Fpnas.68.11.2678  
https://dx.doi.org/10.1093/ajcn/24.11.1294  
 
The three references at the end of the above sentence, i.e. [5–7], refer to papers by Terrence 
Anderson, then professor at the Department of Epidemiology and Biometrics, University of 
Toronto. Thus, they are not papers by Pauling, although the references at the end of the sentence 
makes the reader assume so: 
[5] https://www.mv.helsinki.fi/home/hemila/CC/Anderson_1977.pdf  
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1947567  
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1958969  
 
In the third paragraph Vorilhon continues: 
“However, later trials failed to corroborate this preventive effect of vitamin C supplementation 
[8–10].” 
The three references 8-10 refer to two reviews published in 1975 ([8] Dykes 1975 and [9] 
Chalmers 1975 and) and one RCT published also in 1975 ([10] Karlowski 1975). 
In our Cochrane review we briefly comment on those three papers from the year of 1975 as 
follows: 
“In a meta-analysis, Chalmers 1975 calculated an unweighted average of the treatment effect in 
seven placebo-controlled trials and found that colds in vitamin C groups were 0.11 ± 0.24 (standard 
error (SE)) days shorter which is not a statistically or clinically significant difference. In a 
qualitative review on vitamin C and the common cold published in the same year, Dykes 1975 also 
concluded that vitamin C had no effect on colds. 
However, it has subsequently been pointed out that the influential reviews by Chalmers 1975 
and Dykes 1975 contain serious errors (Hemilä 1995;Hemilä 1996c;Hemilä 2006a). Hemilä 1995 
showed that after extraction of correct data from the trial reports, correction of errors in 
calculations, and restriction to trials in which at least 1 g/day of vitamin C had been used, as 
Pauling had proposed, Chalmers 1975 would have calculated an eight times higher estimate of the 
vitamin C effect: 0.93 ± 0.22 (SE) days reduction in the duration of colds. Furthermore, both 
Chalmers 1975 and Dykes 1975 placed considerable weight on the double-blind, placebo-
controlled trial carried out by Karlowski 1975a at the National Institutes of Health (NIH), which 
concluded that a statistically significant benefit of vitamin C supplementation was simply explained 
by the placebo effect. However, it has been shown that the placebo effect explanation in the 
Karlowski 1975a paper was not consistent with their own data (Chalmers 1996; Hemilä1996a; 
Hemilä 1996d; Hemilä 2006a; Hemilä 2006c)” 
see page 3, right-hand column: 
https://doi.org/10.1002/14651858.CD000980.pub4   
https://www.mv.helsinki.fi/home/hemila/CC/2013_Coch_Colds_CD000980.pdf  
https://helda.helsinki.fi/handle/10138/225864  
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The Dykes-Meier (1975) review [8] 
http://dx.doi.org/10.1001/jama.1975.03240220051025  
and 
The Chalmers (1975) review [9] 
http://dx.doi.org/10.1016/0002-9343%2875%2990127-8  
 
were shown to be erroneous two decades ago 
http://dx.doi.org/10.1080/07315724.1995.10718483  
http://www.mv.helsinki.fi/home/hemila/H/HH_1995.pdf  
https://helda.helsinki.fi/handle/10138/42358  
http://dx.doi.org/10.1016/S0899-9007%2896%2900223-7  
http://www.mv.helsinki.fi/home/hemila/H/HH_1996_NUT.pdf  
https://helda.helsinki.fi/handle/10138/225877  
https://helda.helsinki.fi/handle/10138/20335  (pp. 36-45) 
 
 
The Karlowski (1975) trial [10] 
http://dx.doi.org/10.1001/jama.1975.03240220018013  
 
was shown to be analyzed erroneously also two decades ago: 
http://dx.doi.org/10.1016/0895-4356%2896%2900189-8  
http://www.mv.helsinki.fi/home/hemila/H/HH_1996_JCE.pdf  
https://helda.helsinki.fi/handle/10138/225872  
http://dx.doi.org/10.1016/0895-4356%2896%2900190-4  
http://dx.doi.org/10.1016/0895-4356%2896%2900191-6  
http://www.mv.helsinki.fi/home/hemila/H/HH_1996_JCE2.pdf  
https://helda.helsinki.fi/handle/10138/225873  
http://dx.doi.org/10.1002/sim.2347  
http://www.mv.helsinki.fi/home/hemila/H/2006_L_SIM.pdf  
https://helda.helsinki.fi/handle/10138/228098  
https://helda.helsinki.fi/handle/10138/20335  (pp. 21-27)  
 
 
These references are listed in our Cochrane review. Thus, had Vorilhon read our Cochrane 
review, they would have seen that their references [8-10] were erroneous in the context.  
Authors of any meta-analysis should take some time to familiarize themselves with the field. 
 
